Mirae Asset Global Investments Co. Ltd. acquired a new position in Solventum Corporation (NYSE:SOLV – Free Report) during the third quarter, HoldingsChannel reports. The institutional investor acquired 36,857 shares of the company’s stock, valued at approximately $3,249,000.
A number of other institutional investors have also recently modified their holdings of SOLV. Diamond Hill Capital Management LLC Investment Advisor bought a new position in shares of Solventum during the second quarter valued at $150,066,000. Bank of America Corp DE increased its stake in Solventum by 0.6% during the 1st quarter. Bank of America Corp DE now owns 1,432,780 shares of the company’s stock valued at $93,561,000 after purchasing an additional 9,083 shares in the last quarter. Bank of New York Mellon Corp bought a new stake in Solventum during the 2nd quarter valued at about $61,460,000. Dimensional Fund Advisors LP raised its holdings in Solventum by 44.0% in the first quarter. Dimensional Fund Advisors LP now owns 774,683 shares of the company’s stock worth $50,576,000 after buying an additional 236,659 shares during the last quarter. Finally, KBC Group NV lifted its stake in shares of Solventum by 36.9% in the first quarter. KBC Group NV now owns 632,833 shares of the company’s stock worth $41,324,000 after buying an additional 170,416 shares in the last quarter.
Solventum Stock Performance
Shares of SOLV traded up $3.17 during trading hours on Friday, hitting $90.34. The stock had a trading volume of 3,168,921 shares, compared to its average volume of 1,109,088. The firm has a market capitalization of $15.38 billion, a PE ratio of 101.51, a PEG ratio of 1.24 and a beta of 0.69. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.02 and a quick ratio of 0.74. Solventum Corporation has a 12 month low of $62.38 and a 12 month high of $94.16. The stock has a fifty day moving average price of $87.73 and a 200 day moving average price of $78.70.
Solventum (NYSE:SOLV – Get Free Report) last announced its earnings results on Thursday, November 5th. The company reported $1.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.11. Solventum had a return on equity of 25.09% and a net margin of 17.26%. The business had revenue of $1.95 billion for the quarter, compared to analysts’ expectations of $1.93 billion. During the same period last year, the firm posted $1.50 earnings per share. The business’s revenue for the quarter was down 7.0% on a year-over-year basis. Analysts anticipate that Solventum Corporation will post 7.21 EPS for the current year.
Wall Street Analysts Forecast Growth
Several brokerages recently weighed in on SOLV. Canadian Imperial Bank of Commerce set a $35.00 price target on shares of Solventum in a research report on Wednesday, October 28th. Piper Sandler reaffirmed an “overweight” rating and issued a $110.00 price objective (up from $105.00) on shares of Solventum in a research report on Friday. Weiss Ratings upgraded Solventum from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, August 18th. KeyCorp lifted their target price on Solventum from $93.00 to $102.00 and gave the stock an “overweight” rating in a report on Thursday, August 6th. Finally, Mizuho set a $113.00 price target on Solventum in a research note on Thursday, August 6th. Ten analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Solventum presently has an average rating of “Moderate Buy” and an average price target of $90.27.
Read Our Latest Analysis on SOLV
Solventum News Roundup
Here are the key news stories impacting Solventum this week:
- Positive Sentiment: Solventum earned $1.45 per share on $1.95 billion in revenue, beating consensus estimates of $1.34–$1.35 per share and $1.93 billion in sales. The company raised its 2026 adjusted EPS guidance to $7.20–$7.30 and expects organic sales growth toward the high end of its 2.5%–3.0% range. Solventum Q3 results
- Positive Sentiment: Analysts lifted price targets: Piper Sandler raised its target to $110 and reaffirmed an overweight rating; Wells Fargo increased its target to $95 while retaining an equal-weight rating. Jefferies raised its target to $98. Piper Sandler rating
- Neutral Sentiment: The company said the 7% year-over-year sales decline (organic sales down 2.8%) reflected, in part, a temporary ERP transition effect: customers had placed advance orders in the prior quarter ahead of the system cutover. Solventum also reported that its separation process was more than 90% complete. Q3 earnings and ERP impact
- Negative Sentiment: Despite the quarterly beat, revenue fell 7% year over year and EPS was down from $1.50 a year ago, highlighting ongoing comparisons and execution risks. Quarterly earnings details
Solventum Profile
Solventum Corporation (NYSE: SOLV) is a global healthcare company that develops products and solutions intended to improve patient care, support healthcare professionals and enhance the efficiency of healthcare systems. Its offerings serve hospitals, clinics, dental practices, laboratories, manufacturers and other healthcare-related organizations.
The company’s portfolio includes medical and surgical products such as wound-care systems, dressings, skin-protection products, sterilization assurance products and solutions used in operating rooms.
Featured Stories
- Five stocks we like better than Solventum
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Want to see what other hedge funds are holding SOLV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Solventum Corporation (NYSE:SOLV – Free Report).
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.
